Enhanced anti-tumor effects of fluorouracil against gastric cancer by 5-aza-2'-deoxycytidine and trichostatin A

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Enhanced anti-tumor effects of fluorouracil against gastric cancer by 5-aza-2'-deoxycytidine and trichostatin A

3rd World Congress on Cancer Science & Therapy

October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Shilian Hu

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Gastric cancer is one of the most common malignant tumors in the world, and only China contributes to almost half of all global new cases each year. Our previous studies have shown that the promoter hypermethylation of RUNX3 and E-cadherin plays an important role in the occurrence and development of gastric cancer. In this study, we analyzed the gene expression and inhibitive effects of gastric cancer cell lines MKN-45 and SGC-7901 treated with fluorouracil alone and in combination with 5-aza-2'- deoxycytidine (5-Aza-dC) or/and trichostatin A (TSA). Gastric cancer cell lines were treated with fluorouracil, with or without 5-aza- dC or/and TSA for different time and doses, and the inhibitive effects were measured by MTT kit to determine cell proliferation. The promoter methylation status and protein expression of RUNX3 and E-cadherin genes were analyzed by the methods of real- time quantified methylation-specific polymerase chain reaction (RTQ-MSP) and western blot, respectively. Treatment with 5-aza- dC or TSA alone was found not to inhibit the proliferation of gastric cancer cells as much as fluorouracil did, but the effect had a remarkable enhancement by fluorouracil combined with 5-aza-dC and TSA. The results showed that 5-aza-dC or TSA could reduce methylation and increase expression of RUNX3 and E-cadherin genes, and the combination of 5-aza-dC and TSA increased more, but fluorouracil did not affect their protein expression. Our findings imply that 5-aza-dC and TSA induce strong reactivation of RUNX3 and E-cadherin genes, and have potentials as therapeutic candidates alone or combination with other tumor-targeted drugs in gastric cancer therapy.

Biography :

Shilian Hu has studied gastric cancer diagnostics, epigenetics and therapeutics more than 30 years, during which time she has authored more than 100 peer-reviewed papers. She has served as the editor-chief for the Journal of Chinese Clinical Healthcare and on the editorial boards for the Chinese Journal of Geriatrics. She is also the chairman of Anhui Provincial Health Administration Society and Anhui Provincial Geriatrics Society in China. Prof. Hu is a member of the Scientific Advisory Committees for the Chinese Geriatrics Society, and she has served on numerous review committees for clinical medicine journals and scientific foundations.


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward